Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aspirin and ACE inhibitors

This article was originally published in The Tan Sheet

Executive Summary

Aspirin therapy for heart attack survivors does not negatively influence angiotensin-converting enzyme inhibitor (ACEi) treatment, according to an overview study published in the June issue of the Journal of the American College of Cardiology. Contrary to widespread concerns, "the present results support the early use of ACEi in acute [myocardial infarction], irrespective of whether or not [aspirin] is given," Roberto Latini, MD, Instituto di Richerche Farmacologiche, Milan, Italy, et al., conclude. Data relating to the use or non-use of aspirin were reviewed for nearly 97,000 patients; evidence of negative interactions did not surface, the report says. In an accompanying editorial, Donald Hall, MD, Technical University of Munich, Germany, says the study contradicts previous research and the results are undermined by the fact that the non-aspirin group was smaller and comprised older, sicker patients

You may also be interested in...



People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

PS091297

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel